试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-26
Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia
编号:NCT04607252登记状态:提前终止企业 / 申办者:Fudan University
药物 / 成分:Metformin plus Megestrol acetate、Megestrol Acetate
登记的停止原因(原文):Our clinical trial NCT03241888 showed LNG-IUS had a better treatment efficacy than Megestrol Acetate (MA) alone. The median CR time for MA group, LNG-IUS group and MA plus LNG-IUS group was 7.0±0.3 months, 4.4±1.0 months and 5.7±1.2 months.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-26
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
编号:NCT05191797登记状态:提前终止企业 / 申办者:University of Washington
药物 / 成分:Bomedemstat、Atezolizumab
登记的停止原因(原文):Closed per SRC Low Accrual Policy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-26
IMM-BCP-01 in Mild to Moderate COVID-19
编号:NCT05429021登记状态:提前终止企业 / 申办者:Immunome, Inc.
药物 / 成分:IMM-BCP-01、Placebo
登记的停止原因(原文):Business decision to discontinue the study based on strategic prioritization.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-25
QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
编号:NCT00807612登记状态:提前终止企业 / 申办者:NantCell, Inc.
药物 / 成分:AMG 479、AMG 479、Carboplatin、AMG 479
登记的停止原因(原文):Study was closed due to administrative decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-25
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
编号:NCT04155424登记状态:提前终止企业 / 申办者:Alexion Pharmaceuticals, Inc.
药物 / 成分:Eculizumab
登记的停止原因(原文):Pediatric clinical study is not feasible.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-25
Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder
编号:NCT04262193登记状态:提前终止企业 / 申办者:Wayne State University
药物 / 成分:Suvorexant、Suvorexant Placebo
登记的停止原因(原文):Did not meet enrollment goals.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-25
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
编号:NCT04318444登记状态:提前终止企业 / 申办者:Columbia University
药物 / 成分:Hydroxychloroquine、Placebo oral tablet
登记的停止原因(原文):The Institutional Review Board closed the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-25
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
编号:NCT05897372登记状态:提前终止企业 / 申办者:Iain Bressendorff
药物 / 成分:ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
登记的停止原因(原文):Slow recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
编号:NCT01737827登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:INC280
登记的停止原因(原文):The study recruitment was ended due to difficulties in identifying subjects who meet the eligibility criteria and therefore the study never reached its planned sample size per protocol. The study termination was not due to any safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-24
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
编号:NCT03866798登记状态:提前终止企业 / 申办者:Octapharma
药物 / 成分:Panzyga
登记的停止原因(原文):FDA released Octapharma from the pediatric post marketing requirement.
查看官方原始记录 ↗